TNF-alpha Receptor as Marker for Psoriasis
Title: Soluble tumor-necrosis-factor-alpha receptor
type-1 as a marker of activity of psoriasis vulgaris and effects
of its treatment
Authors: Serwin AB, et al.
Publication: Przegl Lek. 2005;62(2):95-7.
The authors wanted to examine the serum or blood concentration
of soluble tumor necrosis factor alpha type I (sTNF-R1) in patients
with psoriasis, and compare this to the severity of the lesions
and effectiveness of treatment.
In order to do this, the authors enrolled 34 patients and measured
the severity of the psoriatic lesions and serum concentration
of STNF-R1 before and after 2 weeks of treatment. They also enrolled
30 healthy volunteers as control. The severity of psoriatic lesion
was quantified using PASI (Psoriasis Area and Severity Index).
The authors found that:
| |
Before Treatment |
After Treatment |
| PASI |
12.98 +/- 5.77 |
6.17 +/- 2.12 |
| sTNF-R1 |
1.88 +/- 0.41 ng/ml |
1.65 +/- 0.46 ng/ml |
The authors found that the concentration of sTNF-R1 was significantly
lower in the healthy control subjects (1.48 +/- 0.3 ng/ml) as
compared to pre-treatment level in the psoriasis patient.
The authors concluded that there was a significant correlation
between the level of serum tumor necrosis alpha type I with the
severity of psoriasis, and that this level decreased after treatment.
They suggested that sTNF-R1 level could serve as a marker of activity
of psoriasis vulgaris.
